Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.48 |
| ▸ | CTSS | P25774 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6929733 | 0.84 | CTSK (0.47) | CTSKCTSSCA2CACNA1BAAK1 | |
| SCHEMBL12647558 | 0.84 | CTSK (0.47) | CTSKCTSSCA2CACNA1BAAK1 | |
| SCHEMBL1759778 | 0.80 | CTSK (0.50) | CTSKCTSSCA2CACNA1BAAK1 | |
| SCHEMBL1065312 | 0.78 | CA2 (0.55) | CTSKCTSSCA2MAPTNPC1 | |
| SCHEMBL30754110 | 0.77 | NPC1 (0.47) | CTSKCTSSCA2CACNA1BNPC1 | |
| SCHEMBL6832891 | 0.76 | CTSS (0.58) | CTSKCTSSCACNA1BAAK1ALDH1A1 | |
| SCHEMBL2617332 | 0.76 | CTSS (0.58) | CTSKCTSSCACNA1BAAK1ALDH1A1 | |
| SCHEMBL1760151 | 0.76 | CTSK (0.52) | CTSKCTSSCACNA1BNPC1RECQL | |
| SCHEMBL17713482 | 0.74 | CTSK (0.59) | CTSKCTSSCACNA1BALDH1A1MAPT | |
| SCHEMBL12647563 | 0.74 | NPC1 (0.48) | CTSKCTSSCACNA1BAAK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499121-B1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. | HOFFMANN LA ROCHE (CH) | 2015-10-07 | — | — | EP | disclosed |
| US-8354441-B2 | Oxazoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| WO-2011057973-A1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20110112080-A1 | OXAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112080-A1 | OXAZOLINE DERIVATIVES | TAAR1, HCRTR1, NPY1R | CTSK 3622/4885CTSS 3650/4885CA2 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.